XNCR · Xencor Inc · Executive Compensation
$35.40
-1.69 (-4.56%)
At close · Nov 16
Return incl. dividend (before tax)
Q4 2023 earnings call transcript
Market Cap
$2.66B
Shares
75.04M
Volume · Nov 16
1.03M
Avg daily vol (3M)
1.55M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $5,521,205 |
| John Desjarlais | Chief Scientific Officer | $1,982,252 |
| Bart Jan Cornelissen | Chief Financial Officer | $1,642,396 |
| Celia E. Eckert | General Counsel | $1,570,479 |
| Nancy Valente | Former Chief Development Officer | $430,766 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $6,811,829 |
| John Kuch | Former Chief Financial Officer | $4,287,528 |
| Bart Jan Cornelissen | Chief Financial Officer | $3,731,011 |
| Nancy Valente | Chief Development Officer | $2,867,773 |
| John Desjarlais | Chief Scientific Officer | $2,827,992 |
| Celia E. Eckert | General Counsel | $1,971,889 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $7,965,955 |
| Nancy Valente | Chief Development Officer | $5,168,862 |
| John Desjarlais | Chief Scientific Officer | $3,213,094 |
| Allen S. Yang | M.D., Ph.D. Former Chief Medical Officer | $2,944,364 |
| John Kuch | Former Chief Financial Officer | $2,233,493 |
| Celia E. Eckert | General Counsel | $2,021,919 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $7,705,952 |
| John Desjarlais | Chief Scientific Officer | $2,955,047 |
| Allen S. Yang | M.D., Ph.D. Former Chief Medical Officer | $2,810,649 |
| John Kuch | Former Chief Financial Officer | $2,114,941 |
| Celia E. Eckert | General Counsel | $1,892,680 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $5,370,295 |
| John Desjarlais | Chief Scientific Officer | $2,625,325 |
| Allen S. Yang | M.D., Ph.D. Former Chief Medical Officer | $2,437,276 |
| John Kuch | Chief Financial Officer | $1,745,969 |
| Celia E. Eckert | General Counsel | $1,698,869 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Bassil I. Dahiyat | President, Chief Executive Officer and Director | $4,480,925 |
| John Desjarlais | Chief Scientific Officer | $1,870,907 |
| John Kuch | Chief Financial Officer | $1,504,141 |
| Celia E. Eckert | General Counsel | $999,728 |
| Allen S. Yang | Chief Medical Officer | $678,932 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Raymond J. Deshaies | member of the Board of Directors | Appointed | 2025-07-31 |
| Todd Simpson | Board of Directors | Appointed | 2025-05-07 |
| Nancy Valente | Executive Vice President and Chief Development Officer | Resigned | 2025-05-07 |
| Todd Simpson | member of the Board of Directors | Appointed | 2025-03-13 |
| Bart Cornelissen | Senior Vice President and Chief Financial Officer | Appointed | 2024-04-09 |
| John Kuch | Senior Vice President and Chief Financial Officer | Retired | 2023-10-26 |
| Barbara Klencke, M.D. | new member of the Board | Appointed | 2023-09-19 |
| Dr. Allen Yang | executive officer | Terminated | 2023-07-03 |
| Allen Yang | executive officer | Resigned | 2023-04-26 |
| Nancy Valente | Executive Vice President and Chief Development Officer | Appointed | 2023-04-26 |
| Nancy Valente | Board of Directors | Resigned | 2023-04-26 |
| Nancy Valente | Board | Appointed | 2022-09-09 |
| Yujiro S. Hata | Board of Directors | Resigned | 2022-09-09 |
Leadership
- Dr. Bassil I. Dahiyat CEO, Board Member
- Bart Cornelissen CFO
- Bart Jan Cornelissen CFO
- Celia E. Eckert General Counsel
- Barbara Klencke, M.D. Board Member
- Dr. A. Bruce Montgomery Board Member
- Dr. Barbara Klencke Board Member
- Dr. Ellen G. Feigal Board Member
- Dr. Kevin C. Gorman Board Member
- Dr. Raymond J. Deshaies Board Member
- Mr. Kurt A. Gustafson Board Member
- Mr. Richard J. Ranieri Board Member
- Mr. Todd E. Simpson Board Member
- Nancy Valente Board Member
- Raymond J. Deshaies Board Member
- Raymond J. Deshaies, Ph.D. Board Member
- Todd Simpson Board Member
Key facts
CIK
1326732
CUSIP
98401F105
13F (30d)
205 filings
189 filers
Visit website
Investor relations